64 related articles for article (PubMed ID: 36237985)
21. Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR.
Berthold F; Faldum A; Ernst A; Boos J; Dilloo D; Eggert A; Fischer M; Frühwald M; Henze G; Klingebiel T; Kratz C; Kremens B; Krug B; Leuschner I; Schmidt M; Schmidt R; Schumacher-Kuckelkorn R; von Schweinitz D; Schilling FH; Theissen J; Volland R; Hero B; Simon T
Ann Oncol; 2020 Mar; 31(3):422-429. PubMed ID: 32067684
[TBL] [Abstract][Full Text] [Related]
22. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
Park JR; Kreissman SG; London WB; Naranjo A; Cohn SL; Hogarty MD; Tenney SC; Haas-Kogan D; Shaw PJ; Kraveka JM; Roberts SS; Geiger JD; Doski JJ; Voss SD; Maris JM; Grupp SA; Diller L
JAMA; 2019 Aug; 322(8):746-755. PubMed ID: 31454045
[TBL] [Abstract][Full Text] [Related]
23. Tandem Transplant for High-Risk Neuroblastoma: Next Steps in the Era of Precision Medicine.
Bagatell R; Irwin MS
JAMA; 2019 Aug; 322(8):729-731. PubMed ID: 31454025
[No Abstract] [Full Text] [Related]
24. [High-risk neuroblastoma treatment strategy: The experience of the SIOPEN group].
Valteau-Couanet D; Schleiermacher G; Sarnacki S; Pasqualini C
Bull Cancer; 2018 Oct; 105(10):918-924. PubMed ID: 30290975
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.
Berthold F; Ernst A; Hero B; Klingebiel T; Kremens B; Schilling FH; Simon T
Br J Cancer; 2018 Aug; 119(3):282-290. PubMed ID: 29991700
[TBL] [Abstract][Full Text] [Related]
26. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
[TBL] [Abstract][Full Text] [Related]
27. Neuroblastoma.
Matthay KK; Maris JM; Schleiermacher G; Nakagawara A; Mackall CL; Diller L; Weiss WA
Nat Rev Dis Primers; 2016 Nov; 2():16078. PubMed ID: 27830764
[TBL] [Abstract][Full Text] [Related]
28. Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.
Pasqualini C; Dufour C; Goma G; Raquin MA; Lapierre V; Valteau-Couanet D
Bone Marrow Transplant; 2016 Feb; 51(2):227-31. PubMed ID: 26524264
[TBL] [Abstract][Full Text] [Related]
29. Declining childhood and adolescent cancer mortality.
Smith MA; Altekruse SF; Adamson PC; Reaman GH; Seibel NL
Cancer; 2014 Aug; 120(16):2497-506. PubMed ID: 24853691
[TBL] [Abstract][Full Text] [Related]
30. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
Kreissman SG; Seeger RC; Matthay KK; London WB; Sposto R; Grupp SA; Haas-Kogan DA; Laquaglia MP; Yu AL; Diller L; Buxton A; Park JR; Cohn SL; Maris JM; Reynolds CP; Villablanca JG
Lancet Oncol; 2013 Sep; 14(10):999-1008. PubMed ID: 23890779
[TBL] [Abstract][Full Text] [Related]
31. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1.
Seif AE; Naranjo A; Baker DL; Bunin NJ; Kletzel M; Kretschmar CS; Maris JM; McGrady PW; von Allmen D; Cohn SL; London WB; Park JR; Diller LR; Grupp SA
Bone Marrow Transplant; 2013 Jul; 48(7):947-52. PubMed ID: 23334272
[TBL] [Abstract][Full Text] [Related]
32. Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: a Pediatric Oncology Group study: a report from the Children's Oncology Group.
Granger M; Grupp SA; Kletzel M; Kretschmar C; Naranjo A; London WB; Diller L
Pediatr Blood Cancer; 2012 Nov; 59(5):902-7. PubMed ID: 22744917
[TBL] [Abstract][Full Text] [Related]
33. Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: results of SMC NB-2004 study.
Sung KW; Son MH; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ; Lee SK; Choi YS; Lim DH; Kim JS; Kim DW
Bone Marrow Transplant; 2013 Jan; 48(1):68-73. PubMed ID: 22635247
[TBL] [Abstract][Full Text] [Related]
34. Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma.
Saarinen-Pihkala UM; Hovi L; Koivusalo A; Jahnukainen K; Karikoski R; Sariola H; Wikström S
Pediatr Blood Cancer; 2012 Dec; 59(7):1190-7. PubMed ID: 22492714
[TBL] [Abstract][Full Text] [Related]
35. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.
Matthay KK; Reynolds CP; Seeger RC; Shimada H; Adkins ES; Haas-Kogan D; Gerbing RB; London WB; Villablanca JG
J Clin Oncol; 2009 Mar; 27(7):1007-13. PubMed ID: 19171716
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
Zage PE; Kletzel M; Murray K; Marcus R; Castleberry R; Zhang Y; London WB; Kretschmar C;
Pediatr Blood Cancer; 2008 Dec; 51(6):747-53. PubMed ID: 18704922
[TBL] [Abstract][Full Text] [Related]
37. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.
George RE; Li S; Medeiros-Nancarrow C; Neuberg D; Marcus K; Shamberger RC; Pulsipher M; Grupp SA; Diller L
J Clin Oncol; 2006 Jun; 24(18):2891-6. PubMed ID: 16782928
[TBL] [Abstract][Full Text] [Related]
38. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
[TBL] [Abstract][Full Text] [Related]
39. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.
Berthold F; Boos J; Burdach S; Erttmann R; Henze G; Hermann J; Klingebiel T; Kremens B; Schilling FH; Schrappe M; Simon T; Hero B
Lancet Oncol; 2005 Sep; 6(9):649-58. PubMed ID: 16129365
[TBL] [Abstract][Full Text] [Related]
40. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.
Pritchard J; Cotterill SJ; Germond SM; Imeson J; de Kraker J; Jones DR
Pediatr Blood Cancer; 2005 Apr; 44(4):348-57. PubMed ID: 15546135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
